Nykode Therapeutics - Invitation to Capital Markets Day in Oslo on September 27, 2023
o Management to host a Capital Markets Day in Oslo, Norway on September 27 from
2:00 p.m.-4:30 p.m. CET.
o Highlights to be covered include recent developments within our pipeline of
innovative cancer vaccines, with a spotlight on the differentiating factors of
our Nykode technology platform and our leading assets, VB10.16 (wholly owned)
and VB10.NEO (in collaboration with Genentech).
o The event is a live event with physical attendance only. The presentation
slides may be accessed from the Company's website.
Oslo, Norway, September 25, 2023 - Nykode Therapeutics ASA (OSE: NYKD), a
clinical-stage biopharmaceutical company dedicated to the discovery and
development of novel immunotherapies, invites to a Capital Markets Day for
analyst and investors in Oslo on September 27, 2023 from 2:00 p.m.-4:30 p.m.
CET. The event will be hosted as a live event with physical attendance only. The
presentation slides may be accessed from the Company's website.
The Capital Markets Day will feature Nykode's Executive Management Team who will
provide an update on the development and future potential of Nykode's business,
as well as a deep dive into our strategic vision. During this event, we will
present recent developments within our pipeline of innovative therapeutic
vaccines with a spotlight on the differentiating factors of our Nykode
technology platform, an update on our activities within autoimmunity and our
leading oncology assets, VB10.16 (wholly owned) and VB10.NEO (in collaboration
with Genentech, a member of the Roche Group).
For a comprehensive overview of our agenda and additional details, please refer
to the full schedule attached hereto.
Attendance requires registration as spaces are limited. To register for the
physical event, please send an email to ABG Sundal Collier, e-mail:
[email protected] by Tuesday September 26, 2023.
Date and time: September 27, 2023 from 2:00 p.m.-4:30 p.m. CET
Location: ABG Sundal Collier, Ruseløkkveien 26, 8th floor, 0251 Oslo
The archived webcast of last week's Capital Markets Day in New York, including
the presentation by Dr. Bradley Monk, VP and Member of the Board of Directors of
the GOG-Foundation, may be accessed on the following link:
About Nykode Therapeutics
Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to
the discovery and development of novel immunotherapies with a focus on treatment
of cancer and autoimmune diseases. Nykode's modular vaccine technology
specifically targets antigens to APC, which have been shown to induce broad,
strong and long-lasting antigen specific immune responses which correlates with
clinical responses in cancer.
Nykode's lead product candidates are VB10.16, a therapeutic vaccine for the
treatment of HPV16 induced malignancies which demonstrated favorable safety and
efficacy results from its Phase 2 trial for the treatment of cervical cancer